If you have psoriasis, you might take medication and keep close tabs on the weather, your stress level, and other triggers. Should you also watch what's on your plate? A healthy diet -- lots of ...

If you have psoriasis, an infection by bacteria and viruses can cause symptoms to flare. A strep infection, specifically, is a known trigger for guttate psoriasis, a form of the disease that ...

White matter and other changes around the toenails and fingernails can occur with psoriasis or nail fungus. However, fungal infections are contagious, and psoriasis is not. The causes and ...

It can be difficult to tell the difference between seborrheic dermatitis vs. psoriasis when symptoms appear only on the scalp. Both conditions can cause scaly, red patches, but the specific appearance ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window For patients with plaque or guttate psoriasis, home-based phototherapy proved to be least as effective as office-based ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its first approval in March this year for the treatment of psoriatic arthritis.

Hand and foot psoriasis impairs patients´ ability to function, impacts them financially, and chips away at their self-worth. Dermatology nurses play an important role with these patients in ...

Psoriasis affects about 3% of all adults in the United States, and Asian Americans have a lower-than-average risk for psoriasis. However, it's believed that psoriasis may be underdiagnosed among ...

The latest additions include weight-loss drugs Ozempic and Wegovy, as well as treatments inlcuding Trelegy Ellipta for asthma and Otezla for psoriatic arthritis. Several cancer medications are ...

on fears that having both Otezla and deucravacitinib would allow the combined company to corner the market for psoriasis pills. Sales of PDE4 inhibitor Otezla grew 13% in the third quarter to $609 ...